Indeed, inhibitors of TGFβ signalling, including Galunisertib, NIS793, and LY364947, have all reached clinical testing for a variety of solid tumours, though concerns remain regarding tumour-suppressor roles in cancer cells for this signalling axis [7,70,71,72,73]. Here, TGFB1 is linked to cancer.